active TMS: Transcranial magnetic stimulation using MagVenture XP Orange Stimulator using active side of MagVenture Cool-B70 coil
sham TMS: Sham transcranial magnetic stimulation using MagVenture XP Orange Stimulator, flipping the active side of the MagVenture Cool-B70 coil
Study summary
The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Clinically established or probable PD
* Clinical Diagnostic Criteria for Parkinson's Disease
* Peak-of-dose levodopa-induced dyskinesia.
* Stable antiparkinsonian medicine for at least four weeks.
* Signed informed consent.
Exclusion Criteria:
* Psychiatric disorders.
* Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin).
* Regular usage of benzodiazepines and opioids (more than once per week).
* History of neurological disease other than Parkinson's disease.
* History of epilepsy/conditions associated with increased risk to seizure-induction through TMS.
* Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS.
* Contraindications for MRI scan
* Female participants of childbearing age must not be pregnant and that they must use contraception during the trial.
* Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.
Primary outcome measure(s)
Unified Dyskinesia Rating Scale (UDysRS) — Baseline (usual medication intake) and up to 40 minutes after taking 150 % of normal morning levodopa dose as Madopar Quick UDysRS utilizes rater information, patient self-report and objective measures of dyskinesia to provide assessments of impairment and disability due to dyskinesia.The UDysRS total score ranges from 0 to 104 with a lower score indicating less dyskinesia.
Dyskinesia onset time — Baseline (usual medication intake) and up to 40 minutes after taking 150 % of normal morning levodopa dose as Madopar Quick The onset time of dyskinesia in minutes after levodopa administration
Trial sites (1)
Facility
City
Region
Status
DRCMR
Hvidovre
Denmark
Recruiting
More Danish Research Centre for Magnetic Resonance trials in Denmark
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.